Kurt Huber

Showing 1-14 of 14 articles

Coronary interventions

Safety and Efficacy of Ticagrelor Monotherapy According to Drug-Eluting Stent Type: The TWILIGHT-STENT Study

Baber U, Sharma S, Giustino G, Sartori S, Nicolas J, Goel R, Mehta S, Cohen D, Angiolillo D, Zhang Z, Camaj A, Cao D, Briguori C, Dudek D, Escaned J, Huber K, Collier T, Kornowski R, Kunadian V, Moliterno DJ, Ohman EM, Weisz G, Gil R, Krucoff M, Kaul U, Oldroyd K, Sardella G, Shlofmitz R, Witzenbichler B, Kastrati A, Han Y, Steg P, Pocock S, Gibson CM, Mehran R

August 26, 2021 | 10.4244/EIJ-D-21-00721

Coronary interventions

Culprit lesion location and outcomes in patients with multivessel disease and infarct-related cardiogenic shock: a core laboratory analysis of the CULPRIT-SHOCK trial

Hauguel-Moreau M, Barthélémy O, Farhan S, Huber K, Rouanet S, Zeitouni M, Guedeney P, Hage G, Vicaut E, Zeymer U, Desch S, Thiele H, Montalescot G

August 6, 2021 | 10.4244/EIJ-D-20-00561

Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices

Chieffo A, Dudek D, Hassager C, Combes A, Gramegna M, Halvorsen S, Huber K, Kunadian V, Maly J, Møller J, Pappalardo F, Tarantini G, Tavazzi G, Thiele H, Vandenbriele C, Van Mieghem N, Vranckx P, Werner N, Price S

July 20, 2021 | 10.4244/EIJY21M05_01

EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic

Chieffo A, Stefanini G, Price S, Barbato E, Tarantini G, Karam N, Moreno R, Buchanan G, Gilard M, Halvorsen S, Huber K, James S, Neumann F, Möllmann H, Roffi M, Tavazzi G, Mauri Ferre J, Windecker S, Dudek D, Baumbach A

June 25, 2020 | 10.4244/EIJY20M05_01

Coronary interventions

Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial

Fabris E, van't Hof A, Hamm C, Lapostolle F, Flensted Lassen J, Goodman S, ten Berg J, Bolognese L, Cequier A, Chettibi M, Hammett C, Huber K, Janzon M, Merkely B, Storey R, Zeymer U, Cantor W, Rousseau H, Vicaut E, Montalescot G

May 15, 2017 | 10.4244/EIJ-D-16-00965

Coronary interventions

Bivalirudin in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: uncertainties almost clarified

Huber K, Verheugt F

March 20, 2017 | 10.4244/EIJV12I16A315

Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement

Capodanno D, Lip G, Windecker S, Huber K, Kirchhof P, Boriani G, Lane D, Gilard M, Collet J, Valgimigli M, Byrne R

January 22, 2015 | 10.4244/EIJV10I9A174

Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force

Gorenek B, Blomström-Lundqvist C, Terradellas J, Camm A, Hindricks G, Huber K, Kirchhof P, Kuck K, Kudaiberdieva G, Lin T, Raviele A, Santini M, Tilz R, Valgimigli M, Vos M, Vrints C, Zeymer U, Kristiansen S

January 22, 2015

An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents

Katsaros K, Kastl S, Krychtiuk K, Hutter R, Zorn G, Maurer G, Huber K, Wojta J, Christ G, Speidl W

June 20, 2014 | 10.4244/EIJV10I2A36

Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care** and Thrombosis of the European Society of Cardiology

Hamon M, Pristipino C, Di Mario C, Nolan J, Ludwig J, Tubaro M, Sabaté M, Mauri Ferre J, Huber K, Niemela K, Haude M, Wijns W, Dudek D, Fajadet J, Kiemeneij F

March 22, 2013 | 10.4244/EIJV8I11A192

Time-related impact of distal embolisation on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation

De Luca G, Gibson CM, Huber K, Dudek D, Cutlip D, Zeymer U, Gyöngyösi M, Bellandi F, Noc M, Arntz H-R, Maioli M, Secco G, Zorman S, Gabriel H, Emre A, Rakowski T, van't Hof A

August 24, 2012 | 10.4244/EIJV8I4A74

Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update

Cuisset T, Valgimigli M, Mudra H, Mueller O, Wijns W, Huber K

May 25, 2010

Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions

Cuisset T, Mudra H, Mueller O, Vogt P, Angelillo-Scherrer A, Huber K

August 20, 2008

Gender-related outcome following percutaneous coronary intervention for ST-elevation myocardial infarction: data from the Austrian acute PCI registry

Suessenbacher A, Doerler J, Alber H, Aichinger J, Altenberger J, Benzer W, Christ G, Globits S, Huber K, Karnik R, Norman G, Siostrzonek P, Zenker G, Pachinger O, Weidinger F

August 20, 2008

1

Latest news

Three-year TAVI outcomes for BAV vs TAV

FREE ARTICLE - Dao Zhou et al.

January 20, 2022

Percutaneous management of left ventricular assist device outflow graft obstruction

FREE ARTICLE - Aleksandra Gasecka et al.

January 19, 2022

EuroCTO Club Consensus on Dual Lumen Microcatheters for CTO Recanalisation; Predicting Radial Crossover in ACS, the MATRIX score; DAPT duration for BRS; and more…

December 17, 2021

Lipid-rich plaque density and LDL-C in statin-treated vs statin-naïve patients

FREE ARTICLE - Rebecca Torguson et al.

January 17, 2022

Redo transcatheter mitral valve replacement in mitral annular calcification

FREE ARTICLE - Jennifer Jdaidani et al

January 13, 2022

TAVI vs SAVR in bicuspid aortic valve stenosis

FREE ARTICLE - Monil Majmundar et al.

January 12, 2022

Management of MR patients undergoing TMVI screening

FREE ARTICLE - Sebastian Ludwig et al.

January 7, 2022

Valvular disease